###begin article-title 0
###xml 117 122 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
###end article-title 0
###begin p 1
###xml 27 49 27 49 <email xmlns:xlink="http://www.w3.org/1999/xlink">brad.jones@utoronto.ca</email>
###xml 71 96 71 96 <email xmlns:xlink="http://www.w3.org/1999/xlink">mario.ostrowski@gmail.com</email>
CORRESPONDENCE Brad Jones: brad.jones@utoronto.ca; OR Mario Ostrowski: mario.ostrowski@gmail.com
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 354 355 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 627 628 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 730 731 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 81 111 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 113 118 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 290 295 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 389 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 443 448 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 516 521 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 568 573 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 658 663 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 712 717 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 984 989 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1078 1083 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Progressive loss of T cell functionality is a hallmark of chronic infection with human immunodeficiency virus 1 (HIV-1). We have identified a novel population of dysfunctional T cells marked by surface expression of the glycoprotein Tim-3. The frequency of this population was increased in HIV-1-infected individuals to a mean of 49.4 +/- SD 12.9% of CD8+ T cells expressing Tim-3 in HIV-1-infected chronic progressors versus 28.5 +/- 6.8% in HIV-1-uninfected individuals. Levels of Tim-3 expression on T cells from HIV-1-infected inviduals correlated positively with HIV-1 viral load and CD38 expression and inversely with CD4+ T cell count. In progressive HIV-1 infection, Tim-3 expression was up-regulated on HIV-1-specific CD8+ T cells. Tim-3-expressing T cells failed to produce cytokine or proliferate in response to antigen and exhibited impaired Stat5, Erk1/2, and p38 signaling. Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1-specific T cells. Thus, Tim-3 represents a novel target for the therapeutic reversal of HIV-1-associated T cell dysfunction.
###end p 3
###begin p 4
###xml 51 54 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Abbreviations used: bDNA, branched-chain DNA; CEF, CMV/EBV/Influenza; CIRC, Canadian Immunodeficiency Research Collaborative; HAART, highly active antiretroviral therapy; MFI, mean fluorescence intensity; mRNA, messenger RNA; P+I, PMA/Ionomycin; SEB, staphylococcus enterotoxin B; sTIM-3, soluble TIM-3.
###end p 4
###begin p 5
R.B. Jones and L.C. Ndhlovu contributed equally to this paper.
###end p 5
###begin p 6
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1000 1001 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1003 1004 995 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1006 1008 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1009 1011 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1353 1355 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1357 1359 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1361 1363 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1365 1367 1357 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1368 1370 1360 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1569 1570 1561 1562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1779 1781 1771 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1783 1785 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1928 1929 1920 1921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2012 2014 2004 2006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 2016 2018 2008 2010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 2228 2229 2220 2221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 45 48 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 195 200 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 364 369 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 413 418 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 479 484 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 562 567 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 860 865 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1100 1105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1294 1298 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
###xml 1308 1311 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1315 1330 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 1336 1341 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1345 1351 <span type="species:ncbi:9606">humans</span>
###xml 1476 1481 <span type="species:ncbi:10090">mouse</span>
###xml 1482 1486 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1551 1556 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1902 1907 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1912 1915 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
It is clear from many studies that HIV-1- or SIV-specific CD8+ and CD4+ T cell responses have an important role in containing viral replication (1-5). However, in most cases cellular immunity to HIV-1 proves incapable of long-term control of viremia and, without antiretroviral therapy, progression to AIDS occurs. The failure of the host immune system to contain HIV-1 is related to the functional impairment of HIV-1-specific CD8+ and CD4+ T cells that accompanies progressive HIV-1 infection, a phenomenon which is referred to as T cell exhaustion (6-17). In HIV-1 infection, the deterioration of the T cell response follows a characteristic pattern: proliferative capacity, cytotoxic potential, and the ability to produce IL-2 are lost early, whereas the production of IFN-gamma is more enduring. Ultimately, the majority of T cells chronically exposed to HIV-1 antigens enter into a state of dysfunction and, as disease advances, even the ability to produce IFN-gamma is progressively impaired (7, 8, 18-22). The causal relationship between this progressive T cell exhaustion and high levels of HIV-1 replication in progressive infection remains unclear. Recently, signaling through PD-1 was shown to play an important role in T cell exhaustion in three models of chronic viral infection: LCMV in mice, SIV in rhesus macaques, and HIV-1 in humans (12, 13, 15, 23-25). Blockade of the PD-1-PD-L1 signaling pathway results in enhanced T cell responses and viral control in mouse LCMV infection, as well as in enhanced survival and proliferation of HIV-1-specific CD8+ T cells in vitro. Increased levels of total cytokine production and increased frequencies of cells producing cytokine in response to antigen are also induced in 6-d in vitro cultures treated with anti-PD-L1 (12, 15). However, it has been demonstrated that there is no direct relationship between the level of PD-1 expression of an HIV-1- or SIV-specific CD8+ T cell and the ability of that cell to produce cytokine upon ex vivo stimulation (13, 25). This has lead to the suggestion that the enhanced levels of total cytokine production observed in vitro with the addition of anti-PD-L1 is the result of greater survival and expansion of antigen-specific CD8+ T cells rather than improved functionality on a per-cell basis. These data suggest that PD-1 expression marks a population exhibiting features of relatively early T cell exhaustion, where cell survival and proliferation are impaired but cytokine production remains intact. Thus, the mechanisms leading to advanced stages of T cell exhaustion, where cytokine production becomes impaired, remain largely undefined.
###end p 6
###begin p 7
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 320 322 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 474 476 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 478 480 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 741 743 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 745 747 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 981 982 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1089 1091 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1093 1095 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 912 918 <span type="species:ncbi:9606">humans</span>
Tim-3 (T cell immunoglobulin and mucin domain-containing molecule 3) is an Ig superfamily member that was identified as a specific cell surface marker of mouse Th1 CD4+ T cells (26). Interaction of mouse Tim-3 with its ligand, galectin-9, regulates Th1 responses by promoting the death of IFN-gamma-producing Th1 cells (27). In mice, blocking the interaction of Tim-3 with its ligands prevents the acquisition of transplantation tolerance induced by costimulatory blockade (27, 28). Furthermore, Tim-3-deficient mice are refractory to the induction of high-dose tolerance in an experimental autoimmune encephalomyelitis model, and anti-Tim-3 monoclonal antibody treatment of SJL/J mice exacerbated experimental autoimmune encephalomyelitis (26, 29). These results indicate that Tim-3 plays a role in suppressing Th1-mediated immune responses, at least partially through the termination of effector Th1 cells. In humans, a defect in up-regulation of Tim-3 on IFN-gamma-producing CD4+ T cells has been implicated as a contributing factor to the pathology associated with multiple sclerosis (30, 31). No study has yet examined the role of Tim-3 in chronic viral infection.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 expression on T cells correlates with clinical parameters of progression in HIV-1-infected individuals
###end title 9
###begin p 10
###xml 399 400 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 765 780 757 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, a and b</xref>
###xml 824 825 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 973 988 965 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, a and b</xref>
###xml 1013 1014 1005 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1018 1019 1010 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1085 1093 1077 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 1126 1127 1118 1119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1155 1163 1147 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 1201 1202 1193 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1206 1207 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1291 1292 1283 1284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1320 1328 1312 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 1433 1435 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1460 1461 1452 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1508 1509 1500 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1513 1514 1505 1506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1536 1544 1528 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 1573 1574 1565 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1621 1622 1613 1614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1626 1627 1618 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1647 1655 1639 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 1793 1794 1785 1786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1799 1800 1791 1792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1818 1819 1810 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2015 2016 2007 2008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2020 2021 2012 2013 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2029 2030 2021 2022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2090 2098 2082 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 c</xref>
###xml 2263 2271 2255 2263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 e</xref>
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 568 573 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 943 948 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1055 1060 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1697 1702 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1911 1916 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2153 2158 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We profiled Tim-3 expression by flow cytometry on PBMC from 9 HIV-1-uninfected individuals and 31 treatment-naive, acute/early, and chronically HIV-1-infected subjects (Canadian Immunodeficiency Research Collaborative [CIRC] cohort) that included both viral controllers (nonprogressors) and progressors using a polyclonal anti-Tim-3 antibody. We observed elevated frequencies of Tim-3-expressing CD8+ T cells in acute/early and chronic progressive HIV-1-infected individuals, but not in viral controllers, relative to uninfected individuals (mean 28.5 +/- SD 6.8% for HIV-1-uninfected versus 52.2 +/- 19.0% for acutely/early infected individuals [P = 0.0015], 49.4 +/- 12.9% for chronic progressors [P = 0.0003], and 31.6 +/- 7.3% for viral controllers [P = 0.48]; Fig. 1, a and b). Tim-3 expression was also elevated on CD4+ T cells from acutely/early infected individuals and chronic progressors, as compared with both viral controllers and HIV-1-uninfected individuals (Fig. 1, a and b). The frequency of Tim-3+ CD8+ T cells correlated positively with HIV-1 viral load (P < 0.0001; Fig. 1 d) and inversely with absolute CD4+ T cell counts (P < 0.0001; Fig. 1 d). Similarly, the frequencies of Tim-3+ CD4+ T cells were significantly correlated with viral load (P = 0.0087) and absolute CD4+ T cell counts (P = 0.0273; Fig. 1 d). T cell activation, as reported by CD38 expression, is an additional predictor of disease progression (32). CD38 expression on CD8+ T cells correlated with the frequency of Tim-3+ CD8+ T cells (P < 0.0001; Fig. 1 d), and CD38 expression on CD4+ T cells correlated with the frequency of Tim-3+ CD4+ T cells (P < 0.05; Fig. 1 d). In acute/early and chronic progressive HIV-1 infection, increased expression of both Tim-3 and CD38 manifested as a frequent dual Tim-3+ CD38+ population of CD8+ T cells (Fig. S1, available at ). In a separate cohort of 60 treatment-naive acutely/early HIV-1-infected individuals (OPTIONS cohort), we observed an analogous increase in the frequency of Tim-3+ CD8+ and CD4+ T cells as assessed with a monoclonal anti-Tim-3 antibody (Fig. 1 c and Fig. S2 a). Similar positive correlations between HIV-1 viremia, CD38, and Tim-3 expression on T cells were also observed in this acute/early infection cohort (Fig. 1 e).
###end p 10
###begin p 11
###xml 0 128 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3 is up-regulated on T cells in HIV-1 infection, and its expression correlates with parameters of HIV-1 disease progression.</bold>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 639 640 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 648 649 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 819 818 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 975 976 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 993 994 993 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1002 1003 1002 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1363 1364 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1398 1399 1398 1399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1455 1456 1455 1456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1752 1753 1752 1753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1761 1762 1761 1762 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1790 1791 1790 1791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 265 269 <span type="species:ncbi:9925">goat</span>
###xml 463 468 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 506 511 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 550 554 <span type="species:ncbi:9925">goat</span>
###xml 692 697 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 802 807 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 822 827 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 867 872 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 921 925 <span type="species:ncbi:9925">goat</span>
###xml 1060 1065 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1143 1148 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1304 1309 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 is up-regulated on T cells in HIV-1 infection, and its expression correlates with parameters of HIV-1 disease progression. (a) PBMCs from HIV-1-infected and uninfected subjects were stained with antibodies against CD4, CD8, CD3, and a biotinylated polyclonal goat anti-Tim-3 antibody, followed by a secondary streptavidin-APC conjugate. Plots show events gated on the CD3+ population, and subsequently on the CD8+ or CD4+ populations, from a representative HIV-1-uninfected subject and a chronically HIV-1-infected subject. Biotinylated normal goat serum was used as a negative control. (b) The percentages of Tim-3+ cells within CD8+ and CD4+ T cell populations are indicated for nine HIV-1-uninfected individuals and 31 individuals from the CIRC cohort separated into three groups: acute/early HIV-1 infected (7), HIV-1-infected chronic progressors (16), and HIV-1-infected viral controller (8), using polyclonal goat anti-Tim-3 antibody. (c) The percentages of Tim-3+ cells within CD8+ and CD4+ T cell populations are indicated for 60 treatment-naive HIV-1-infected individuals from the UCSF OPTIONS cohort of primary infection and 9 HIV-1-uninfected controls using PE-conjugated monoclonal anti-Tim-3 antibody. Subjects from the CIRC cohort were defined as follows: acute/early = infected with HIV-1 < 4 mo; chronic progressor = infected > 1 yr with CD4+ T cell count decline >50 cells/mm3/yr, viral controller infected >1 yr, no evidence of CD4+ T cell count decline, and viral load <5,000 copies/ml bDNA. Characteristics of the OPTIONS acute/early infection cohort are detailed in Materials and methods. Statistical analyses for both cohorts were performed using the Mann-Whitney test. (d and e) Correlations between Tim-3 expression on CD8+ and CD4+ T cells and viral load, CD4+ T cell counts, and levels of CD38 expression among individuals with available clinical data from the CIRC cohort (d) and OPTIONS cohort (e). Shown for the CIRC cohort are Tim-3 levels determined using a polyclonal anti-Tim-3 antibody. Confirmatory experiments were performed using a PE-conjugated monoclonal anti-Tim-3, and a tight correlation between the two datasets was observed, with slightly higher frequencies of Tim-3-expressing cells observed with polyclonal anti-Tim-3 antibody (Fig. S2 a). For the OPTIONS cohort, levels of Tim-3 expression were assessed using the monoclonal anti-Tim-3 antibody. Statistical analyses were performed using the Spearman's rank correlation test. Solid lines show the mean. Fig. S2 is available at .
###end p 11
###begin title 12
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 is up-regulated on HIV-1-specific CD8+ T cells in progressive HIV-1 infection
###end title 12
###begin p 13
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 375 364 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, a&#8211;e</xref>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 833 817 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, c and e</xref>
###xml 911 912 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 120 125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 230 235 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 252 255 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 378 381 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 484 487 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 697 702 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 893 898 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1214 1219 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 expression on antigen-specific CD8+ T cells was examined in HLA-A*0201+, HLA-B*0702+, and HLA-B*0801+ chronically HIV-1-infected individuals using matched MHC-I pentamers. We observed significantly higher levels of Tim-3 on HIV-1-specific versus CMV-specific CD8+ T cells (P = 0.0065 by mean fluorescence intensity [MFI], P = 0.0026 by percentage of Tim-3+; Fig. 2, a-e). CMV-specific CD8+ T cells exhibited low levels of Tim-3 expression, with the exception of one response to CMV-pp65-TPRVTGGGAM, which exhibited high levels of Tim-3 expression as measured by MFI, observed in cells from an individual with AIDS (absolute CD4 count, 132 cells/mul). Tim-3 expression was heterogenous among HIV-1-specific responses, with some exhibiting very high levels of Tim-3, whereas others exhibited only baseline levels (Fig. 2, c and e). The heterogeneity observed in Tim-3 expression levels on HIV-1-specific CD8+ T cells cannot be attributed solely to intersubject variability, as responses with high levels of Tim-3 expression were frequently observed contemporaneously with responses exhibiting low levels of Tim-3 expression within the same individual. This leads us to speculate that Tim-3 expression may mark HIV-1-specific T cells with differing functional capacities.
###end p 13
###begin p 14
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3 is expressed at elevated levels on HIV-1&#8211;specific CD8<sup>+</sup> T cells in progressive HIV-1 infection.</bold>
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 654 655 654 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 738 739 738 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 165 170 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 264 267 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 289 294 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 389 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 460 463 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 525 530 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 562 567 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 702 707 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 722 725 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Tim-3 is expressed at elevated levels on HIV-1-specific CD8+ T cells in progressive HIV-1 infection. PBMC from HLA-A*0201+, HLA-B*0702+, and HLA-B*0801+ chronically HIV-1-infected individuals from the CIRC cohort were stained with matched HLA pentamers presenting CMV, EBV, influenza, and HIV-1 epitopes, and with anti-Tim-3. (a) Shown are representative flow cytometry data from one HIV-1-infected chronic progressor using HLA-A*0201 pentamers presenting the CMV-pp65 epitope NLVPMVATV, the EBV-Bmlf1 epitope GLCTLVAML, the HIV-1-Pol epitope ILKEPVHGV, and the HIV-1-Gag epitope SLYNTVATL. (b-e) Compiled Tim-3 expression data from chronic progressors (n = 41) is shown for pooled Tim-3 expression on HIV-1 (b and d) and CMV-specific CD8+ T cell responses from chronic progressors' individual epitope responses (c and e). Statistical analyses comparing pooled responses were performed using the Mann-Whitney test. Solid lines show the mean.
###end p 14
###begin title 15
Reduction of Tim-3 expression upon initiation of highly active antiretroviral therapy (HAART) is correlated with levels of ongoing T cell activation (CD38 expression)
###end title 15
###begin p 16
###xml 164 170 164 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 478 493 478 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, a and b</xref>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 747 748 747 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 853 854 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 969 977 969 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 b</xref>
###xml 1117 1118 1117 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1198 1199 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 418 423 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1154 1159 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1363 1368 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The effect of HAART on Tim-3 expression was studied in seven chronically HIV-1-infected individuals at baseline and at 1, 2, 3, and 6 mo after initiation of HAART (Fig. 3). Four subjects with chronic infection demonstrated a steady decline in Tim-3 levels on both CD4+ and CD8+ T cells with HAART, whereas three subjects (OM 304, 331, and 287) maintained high levels of Tim-3 expression despite achieving undetectable HIV-1 viral loads (<50 copies/ml branched-chain DNA [bDNA]; Fig. 3, a and b; and Fig. S3, available at ). In a mixed-effects longitudinal analysis we observed that CD8+ T cell activation, as measured by CD38 expression, was significantly associated with Tim-3 expression over the period of HAART. Levels of CD38 expression on CD8+ T cells, as measured by either percentage or MFI, were associated with levels of Tim-3 expression on CD8+ T cells during therapy, with a 0.38% higher Tim-3 expression per 1% higher CD38 expression (SE = 0.11; P = 0.001; Fig. 3 b) and a 0.7% higher Tim-3 expression per unit higher CD38 MFI (SE = 0.19; P = 0.001). These effects remained unaltered when adjusted for CD4+ T cell count. In contrast, neither HIV-1 viral load (P = 0.25) nor absolute CD4+ T cell count (P = 0.07) were significantly associated with Tim-3 expression after HAART. Maintenance of high levels of Tim-3 expression in a subset of chronically HIV-1-infected individuals treated with HAART therapy is thus related to ongoing T cell activation (CD38 expression).
###end p 16
###begin p 17
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of HAART on levels of Tim-3 expression in chronic HIV-1 infection.</bold>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 710 711 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 746 747 746 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 820 821 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 436 441 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 725 730 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of HAART on levels of Tim-3 expression in chronic HIV-1 infection. Seven chronically HIV-1-infected individuals from the CIRC cohort were sampled at baseline and at 1, 2, 3, and 6 mo after initiation of HAART. (a and b) Shown are compiled Tim-3 expression on CD8+ T cells versus months after initiation of HAART (a) and Tim-3 and CD38 expression levels, as determined by flow cytometry, along with absolute CD4+ T cell count and HIV-1 viral load clinical data (b). The six individuals followed for 6 mo achieved undetectable viral loads (bDNA <50 copies/ml). The chart in b summarizes the p-values obtained from a mixed-effects longitudinal analysis studying associations between Tim-3 expression on CD8+ T cells with HIV-1 viral load, CD8+ T cell activation as measured by CD38 expression (MFI), and absolute CD4+ T cell count. The results of this analysis are further outlined in the text, and details are outlined in Materials and methods.
###end p 17
###begin title 18
Tim-3 expression defines a population of dysfunctional Th1/Tc1 cells
###end title 18
###begin p 19
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 262 263 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 271 272 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 343 344 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 371 372 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 435 436 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 449 455 445 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 496 497 492 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 560 561 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 565 566 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 980 981 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 989 990 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1067 1068 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1142 1144 1122 1124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1153 1155 1133 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1169 1184 1149 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, a and b</xref>
###xml 1468 1469 1444 1445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1543 1544 1519 1520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1677 1681 1649 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 1734 1735 1702 1703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1741 1743 1709 1711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1751 1759 1719 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 c</xref>
###xml 1813 1815 1781 1783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1894 1896 1862 1864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1900 1901 1868 1869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1945 1949 1913 1917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 1953 1954 1921 1922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2147 2151 2115 2119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 2227 2229 2195 2197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 2242 2250 2210 2218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 d</xref>
###xml 103 108 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 670 675 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 690 693 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 792 797 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 872 877 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 910 915 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1327 1332 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1525 1530 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We sorted Tim-3+ from Tim-3- populations within both CD8+ and CD4+ T cell subsets using PBMC from both HIV-1-infected and -uninfected individuals and quantified T-bet (Th1), GATA-3 (Th2), and IFN-gamma (Th1) messenger RNA (mRNA) by quantitative PCR. For both CD8+ and CD4+ T cell populations, GATA-3 was expressed at higher levels in the Tim-3- fraction than in the Tim-3+ fraction, whereas T-bet was more highly expressed in the Tim-3+ population (Fig. 4). Despite the Th1/Tc1 character of Tim-3+ cells, we detected the majority of IFN-gamma mRNA in the Tim-3- CD8+ population. We then examined IFN-gamma and TNF-alpha production in response to stimulation with pooled HIV-1-Gag peptides, CMV/EBV/Influenza (CEF) peptides, or staphylococcus enterotoxin B (SEB) in PBMC from 10 acutely/early HIV-1-infected individuals, 10 chronic progressors, 10 viral controllers, and 5 HIV-1-uninfected individuals. In both HIV-1-infected and -uninfected subjects, IFN-gamma production from CD4+ and CD8+ T cells in response to stimulation was observed predominately from the Tim-3- population, with minimal cytokine production observed in either the Tim-3lo or Tim-3hi populations (Fig. 5, a and b). Analogous patterns of cytokine production were observed for acutely/early infected individuals, chronic progressors, viral controllers, and HIV-1-uninfected subjects (Fig. S4, available at ). TNF-alpha and CD107a expression in response to antigen were similarly restricted to Tim-3- cells (Figs. S4 and S5). As a corollary, we identified HIV-1-specific CD8+ T cells by staining with MHC-I tetramers and observed that, in response to cognate peptide, IFN-gamma was produced only by the Tim-3-/lo fraction, with no IFN-gamma production from tetramer+ Tim-3hi cells (Fig. 5 c). Thus, the lack of cytokine secretion from the Tim-3hi population cannot be attributed to an absence of antigen-specific cells. Tim-3hi CD8+ T cells were subsequently sorted from Tim-3-/lo CD8+ T cells using ex vivo PBMC from untreated chronic progressors. Both subsets were stimulated with anti-CD3/anti-CD28, and proliferation was assessed by CFSE dilution. Proliferation of the Tim-3-/lo cells was observed, whereas minimal proliferation was detected in the Tim-3hi population (Fig. 5 d).
###end p 19
###begin p 20
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantitative PCR analysis of T-bet and GATA-3 mRNA in Tim-3</bold>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 72 60 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">versus Tim-3</bold>
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 73 88 73 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T cell subsets.</bold>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 548 549 540 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 552 553 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 576 581 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Quantitative PCR analysis of T-bet and GATA-3 mRNA in Tim-3+versus Tim-3-T cell subsets. PBMCs were stained with monoclonal antibodies to CD3, CD4, CD8, and Tim-3 and sorted into Tim-3+CD8+, Tim-3-CD8+, Tim-3+CD4+, and Tim-3-CD4+ subsets by flow cytometry. RNA was isolated and reverse transcribed. GATA-3, T-bet, TBP, and IFN-gamma transcripts were quantified in triplicate by SYBR real-time PCR. Levels of GATA-3, T-bet, and IFN-gamma expression were normalized to TBP. Shown are normalized quantifications expressed relative to the mean of Tim-3-CD8+ from a representative HIV-1-infected chronic progressor (CIRC cohort). Error bars represent SE.
###end p 20
###begin p 21
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3&#8211;expressing CD8<sup>+</sup> and CD4<sup>+</sup> T cell populations are dysfunctional.</bold>
###xml 438 439 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 447 448 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 631 632 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 639 641 631 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 652 654 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 694 695 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 705 707 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 788 796 780 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 a</xref>
###xml 825 827 817 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 837 839 829 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1402 1403 1390 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1443 1445 1431 1433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1448 1449 1436 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1467 1471 1455 1459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 1474 1475 1462 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1809 1810 1797 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1836 1837 1824 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2149 2150 2137 2138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2160 2161 2148 2149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2180 2181 2168 2169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2288 2289 2276 2277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2299 2300 2287 2288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2319 2320 2307 2308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 98 103 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 476 481 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 761 765 <span type="species:ncbi:9925">goat</span>
###xml 981 986 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1550 1555 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1791 1796 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1820 1825 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2242 2247 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3-expressing CD8+ and CD4+ T cell populations are dysfunctional. (a and b) PBMCs derived from HIV-1-infected and -uninfected individuals were stimulated with pooled peptides or SEB superantigen for 6 h, stained for IFN-gamma, TNF-alpha, and Tim-3 using a polyclonal Tim-3 antibody, and analyzed by multiparametric flow cytometry. (a) Representative flow cytometry plots showing cytokine responses to pooled Gag peptides and SEB in CD8+ and CD4+ T cells from a chronically HIV-1-infected individual (CIRC cohort). We used a three-tiered gating system for analyzing cytokine secretion by Tim-3-expressing cells, considering Tim-3-, Tim-3lo, and Tim-3hi populations. The division between Tim-3- and Tim-3lo populations was determined based on a control normal goat serum staining (as in Fig. 1 a). The division between Tim-3lo and Tim-3hi was set arbitrarily and then consistently applied to all samples (all run in parallel). (b) Compiled flow cytometry data from 10 chronically HIV-1-infected progressors (CIRC cohort). IFN-gamma response percentage for each subset is normalized to the total number of cells within that population. (c) PBMCs from three chronic progressors were stained with an HLA-A*0201-SLYNTVATL pentamer and stimulated with SLYNTVATL peptide or DMSO control. Shown are cytokine production and Tim-3 expression as determined by flow cytometry in a representative subject. (d) CD8+ T cells were sorted into purified Tim-3hiCD8+ T cells and Tim-3-/loCD8+ T cell populations and labeled with CFSE from one of three representative HIV-1-infected individuals. These two populations were then cultured in the presence of anti-CD3 and anti-CD28 monoclonal antibodies for 5 d. Cells where then assessed for the diminution of CFSE as a readout of cell division. (e) PBMCs from HIV-1-uninfected (n = 5) and HIV-1-infected (n = 5) subjects were assessed for levels of intracellular Ki67 antigen expression. Shown are flow cytometry plots displaying Ki67 expression (x axis) by Tim-3 expression as determined with monoclonal anti-Tim-3 (y axis). (f) Shown is a histogram presenting Ki67 staining in comparison to isotype controls in Tim-3- and Tim-3+ populations of CD8+ T cells. (g) Shown is compiled Ki67 staining data from five HIV-1-infected subjects broken down into Tim-3+ and Tim-3- populations of CD8+ T cells. Solid lines show the mean.
###end p 21
###begin p 22
###xml 224 225 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 231 232 231 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 436 437 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 512 513 510 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 515 516 513 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 539 541 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 677 679 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 680 682 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 761 762 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 784 785 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 793 794 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 853 861 851 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 e</xref>
###xml 864 866 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 905 906 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 922 923 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 929 930 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 989 997 987 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 g</xref>
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 608 613 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 813 818 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1342 1347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We costained ex vivo PBMC from five HIV-1-uninfected individuals and 5 HIV-1-infected chronic progressors with Tim-3 and Ki67 antigen. Ki67 antigen is a nuclear protein that is generally expressed only in cells in the late G1, S, G2, and M phases of cell cycle (33). Hence, it is generally used as a marker of proliferating cells. In chronic HIV-1 infection, however, it has been demonstrated that the large majority (92 +/- 5%) of Ki67+ T cells in peripheral blood are activated cells that are arrested in the G0/G1 phases of cell cycle (34). Several studies have noted that Ki67 expression on T cells from HIV-1-infected individuals is associated with dysfunction or anergy (35-37). Consistently with previous studies, we observed elevated frequencies of Ki67+ cells in both the CD4+ and CD8+ T cell subsets of HIV-1-infected versus -uninfected PBMC (Fig. 5 e) (38). Although the large majority of Tim-3+ cells were Ki67-, Ki67+ T cells were greatly enriched for Tim-3-expressing cells (Fig. 5 g, P = 0.0159). Expression of Tim-3 on this population, which has been characterized as activated but arrested in cell cycle, is consistent with our in vitro data showing a lack of proliferation of Tim-3-expressing cells. Collectively, these studies indicate that Tim-3 expression defines a population of activated, but dysfunctional, T cells in HIV-1 infection.
###end p 22
###begin title 23
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Blocking the Tim-3-Tim-3L pathway enhances the functionality of HIV-1-specific T cells
###end title 23
###begin p 24
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 505 513 504 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 a</xref>
###xml 550 551 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 559 560 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 673 688 672 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, b and c</xref>
###xml 950 958 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 d</xref>
###xml 390 395 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 427 432 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 908 913 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To delineate the causal relationship between Tim-3 expression and T cell dysfunction, we tested whether blocking the interaction of Tim-3 with its ligands would restore function in Tim-3-expressing cells. We used a recombinant soluble Tim-3 (sTim-3) glycoprotein to compete for Tim-3 ligands. Addition of sTim-3 enhanced the expansion of CD8+ T cells specific for the HLA-A*0201 restricted HIV-1-Gag epitope SLYNTVATL (SL9) in HIV-1-infected chronic progressors in a dose-dependent manner up to 2 mug/ml (Fig. 6 a). Enhanced proliferation of both CD8+ and CD4+ T cells was also observed when PBMCs from chronic progressors were stimulated with pooled Gag and Nef peptides (Fig. 6, b and c). We corroborated these data by using a blocking anti-Tim-3 mAb clone (2E2) to disrupt the Tim-3 pathway in an analogous proliferation assay experiment. Addition of 10 mug/ml of mAb 2E2 resulted in a profound rescue of HIV-1-Gag T cell proliferative responses (Fig. 6 d).
###end p 24
###begin p 25
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Addition of sTim-3 enhances the proliferation of HIV-1&#8211;specific T cells.</bold>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 402 403 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 407 408 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 544 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 548 549 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1013 1014 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1022 1023 1016 1017 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 629 634 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 905 910 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1077 1082 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1518 1523 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1660 1665 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1743 1748 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1893 1898 <span type="species:ncbi:10090">mouse</span>
Addition of sTim-3 enhances the proliferation of HIV-1-specific T cells. (a) PBMC from a chronically HLA-A0201+ HIV-1-infected individual were stimulated with the SLYNTVATL peptide in the presence of 4, 2, or 1 mug/ml sTim-3, or a control (see Tim-3 expression methods), for 6 d. Cells were stained with HLA-A*0201 SLYNTVATL tetramer and mAbs to CD3, CD8, and anti-Tim-3. Percentages of viable tetramer+ CD8+ T cells were determined by flow cytometry. Each condition was tested in independent triplicate. Shown are mean percentages of tetramer+ CD8+ T cells on day 6 of stimulation. Error bars represent SE. (b and c) PBMCs from HIV-1-infected patients were stained with CFSE, and the effect of 2 mug/ml sTim-3 on cytokine production and proliferation of PBMCs in response to antigen was determined in these individuals over a 5-d stimulation assay. (b) Shown are representative data from one chronically HIV-1-infected individual on day 5 of culture, showing CFSE (x axis) by IFN-gamma production (y axis) in CD8+ and CD4+ T cell populations in response to DMSO (top), pooled HIV-1-derived Gag/Nef peptides (middle) or CEF pooled peptides (bottom) in the presence or absence of either 2 mug/ml sTim-3 or an equal volume of expression control (see Materials and methods). CFSE becomes diluted in cells undergoing proliferation. Thus, cells in the two left quadrants of each plot have proliferated. (c) Shown are summary data for the effect of 2 mug/ml sTim-3 on proliferation in response to Gag from seven chronically HIV-1-infected individuals. P-values were determined by the Wilcoxon matched pairs test. (d) PBMC from an individual with chronic progressive HIV-1 infection were stained with CFSE and stimulated for 7 d with DMSO and pooled HIV-1-Gag peptides or with anti-CD3 and anti-CD28. For each stimulation, the effect of 10 mug/ml of anti-Tim-3 mAb 2E2 was compared with 10 mug/ml of mouse IgG1 isotype control. Shown are flow cytometry plots showing CD3 by CFSE, where diminution of CFSE is indicative of proliferated cells.
###end p 25
###begin p 26
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 951 952 947 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1303 1308 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An additional observation from these experiments is that cells that had undergone proliferation in vitro exhibited high levels of Tim-3 expression (Fig. S6, available at ). Tim-3 up-regulation in response to anti-CD3/anti-CD28 was observed as early as 20 h after stimulation and progressively increased out to at least 120 h (unpublished data). This is consistent with Tim-3 acting as a negative immune regulator, where antigen-stimulated cells perform effector functions and then up-regulate Tim-3 as a means of terminating responses. In reconciling our ex vivo data showing a lack of cytokine production from Tim-3+ cells with published in vitro data demonstrating an association between IFN-gamma production and high levels of Tim-3 expression, there is an important distinction to make. Cells expressing Tim-3 ex vivo have been subjected to chronic stimulation in vivo and are dysfunctional to further in vitro stimulation. In contrast, when Tim-3- cultured cells are stimulated in vitro they perform effector functions, such as producing IFN-gamma, and then up-regulate Tim-3 to dampen these responses. Thus, depending on when one observes these cultures, high levels of Tim-3 and IFN-gamma could be observed in association. This model predicts that in addition to restoring functions of exhausted HIV-1-specific T cells, in vitro treatment with sTim-3 should prolong effector function in response to other antigens. This is supported by examining the level of IFN-gamma production at day 5 of in vitro stimulation with anti-CD3/CD28. Under these conditions, all cells that have undergone division express high levels of Tim-3 (unpublished data). In the presence of sTim-3, these cells consistently express higher levels of IFN-gamma than in the presence of a control (Fig. S7, available at ).
###end p 26
###begin title 27
The Tim-3-expressing T cell population is distinct from the PD-1-expressing population.
###end title 27
###begin p 28
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 349 355 349 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 446 447 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 503 504 503 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 552 553 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 557 558 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 573 574 573 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 714 729 714 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, c and d</xref>
###xml 753 754 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 812 813 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 850 851 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 855 856 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 858 866 858 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 e</xref>
###xml 900 901 900 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 910 911 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 913 921 913 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 f</xref>
###xml 997 1012 997 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, e and f</xref>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 218 223 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 735 740 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Because PD-1 has been identified as a marker of exhausted T cells in HIV-1 infection, we determined whether Tim-3 expression defines the same or a distinct population. PBMC from 10 individuals with chronic progressive HIV-1 infection were costained for Tim-3 and PD-1. Expression was analyzed by flow cytometry after gating on CD8+ or CD4+ T cells (Fig. 7). In 9/10 subjects, Tim-3 and PD-1 were primarily expressed by distinct populations of CD8+ T cells. One subject, OM513, displayed a frequent Tim-3+PD-1+ population (23.6%) but retained both Tim-3+PD-1- and Tim-3-PD-1+ populations (23 and 16.7%, respectively). Similarly, 9/10 subjects showed primarily divergent staining for PD-1 and Tim-3 on CD4+ T cells (Fig. 7, c and d). In HIV-1-specific CD8+ T cells, we observed two patterns of expression: tetramer+ populations were predominantly Tim-3+PD-1- (Fig. 7 e) or they were predominantly Tim-3- and PD-1+ (Fig. 7 f). In both patterns, a minority population coexpressed both Tim-3 and PD-1 (Fig. 7, e and f). Thus, Tim-3 and PD-1 expression define primarily distinct populations.
###end p 28
###begin p 29
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3 and PD-1 are independent surface markers with divergent expression.</bold>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 569 570 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 723 724 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 810 811 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 230 235 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 514 519 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 643 648 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 691 696 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 778 783 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3 and PD-1 are independent surface markers with divergent expression. (a-d) PBMCs were labeled with fluorochrome-conjugated mAbs to CD3, CD8, CD28, PD-1, and Tim-3. (a and b) Shown are flow cytometry plots from 10 chronically HIV-1-infected individuals (CIRC cohort), gated on either the CD3+CD8+ population (a) or the CD3+CD4+ population (b). (c and d) Shown is summary data of the flow cytometry plots displayed in a and b. (e and f) Shown are flow cytometry data analyzing coexpression of Tim-3 and PD-1 on HIV-1-specific CD8+ T cells in comparison with bulk CD8+ T cells in CD8+-enriched PBMC from individuals with chronic progressive HIV-1 infection. Solid lines show the mean. (e) HIV-1-Pol-ILKEPVHGV-specific CD8+ T cells were identified using HLA-A02 tetramers. (f) HIV-1-Nef-TGPGVRYPL-specific CD8+ T cells were identified using HLA-B07 tetramers.
###end p 29
###begin p 30
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 77 85 77 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 a</xref>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 335 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 555 556 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 665 680 665 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8, b and c</xref>
###xml 582 587 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We performed dual staining for Tim-3 and CD25 on both CD4+ and CD8+ T cells (Fig. 8 a). We observed that Tim-3 and CD25 were primarily expressed by distinct populations of T cells. These data demonstrate that Tim-3 expression on CD4+ T cells does not mark a population of classical regulatory T cells. We then determined if the Tim-3hi population could be defined by other cell surface markers that have been used to define the maturation/differentiation status of T cells by costaining for CD57, CD45RA, CD27, CD28, and CCR7 (39-42). Tim-3-expressing CD8+ T cells from chronically HIV-1-infected individuals were distributed across a range of phenotypic profiles (Fig. 8, b and c).
###end p 30
###begin p 31
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3&#8211;expressing CD8<sup>+</sup> T cells are present in diverse phenotypic profiles.</bold>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 627 628 627 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 631 632 631 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 717 719 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 750 752 750 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 839 844 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3-expressing CD8+ T cells are present in diverse phenotypic profiles. (a) PBMCs from HIV-1-uninfected (n = 3) and chronically HIV-1-infected (n = 3) individuals were labeled with fluorochrome-conjugated mAbs to CD3, CD8, CD4, CD25, and Tim-3. Shown are flow cytometry plots gated on the CD3+CD4+ population or the CD3+CD8+ population from two representative individuals. (b) PBMCs from a chronic progressor were labeled with fluorochrome-conjugated mAbs against Tim-3, CD3, CD8, CD28, CD27, CD45RA, CCR7, and CD57, as well as with a dead cell-discriminating marker. Gating was first performed to include only the viable CD3+CD8+ population in subsequent analyses. Shown are phenotypic representations of the Tim-3hi population (blue) versus Tim-3lo population (red). (c) Summary data showing phenotypic profiling for seven chronically HIV-1-infected individuals. Gating for maturation/differentiation markers was determined based on fluorescence minus one controls, and results were analyzed using SPICE software. Shown are the frequencies of populations with the corresponding combination of phenotypic markers, with each individual represented by a single bar.
###end p 31
###begin title 32
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Tim-3+ T cells exhibit impaired Stat5, Erk1/2, and p38 signaling
###end title 32
###begin p 33
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 149 153 149 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 318 322 318 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 558 543 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, a and b</xref>
###xml 664 675 664 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, c&#8211;e</xref>
###xml 704 705 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 176 181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 882 887 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We assessed the kinetics of STAT5, Erk1/2, and p38 phosphorylation (pSTAT5, pErk1/2, and p38, respectively) after stimulation in Tim-3hi versus Tim-3-/lo CD8+ T cells in three HIV-1-infected individuals (43). Tim-3hi CD8+ T cells had higher levels of basal phosphorylation of STAT5, p38, and ERK1/2 compared with Tim-3-/lo CD8+ T cells, and they exhibited lower fold changes in the phosphorylation of these molecules when stimulated in vitro with IL-2 for the STAT5 pathway and with PMA/Ionomycin (P+I) for p38 and ERK1/2 (MAP kinase pathway; Fig. 9, a and b). This impaired signaling response was seen in every stage of differentiation of Tim-3-expressing cells (Fig. 9, c-e). Thus, Tim-3-expressing CD8+ T cells exhibit a blunted change in phosphorylation of preactivated signaling proteins. This is consistent with the model recently proposed by Schweneker et al. (43), in which HIV-1 infection induces chronic activation of T cells, resulting in enhanced basal phosphorylation and perturbed signaling in response to restimulation. The intracellular domain of Tim-3 contains five conserved tyrosine residues but does not contain sequences corresponding to the ITIM consensus, and its downstream signaling targets remain unknown.
###end p 33
###begin p 34
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tim-3&#8211;expressing cells exhibit impaired Stat-5, p35, and Erk1/2 signaling in response to stimuli.</bold>
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 202 206 202 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 580 582 580 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 592 596 592 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/lo</sup>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1208 1209 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1222 1223 1222 1223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1262 1263 1262 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1266 1267 1266 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1302 1303 1302 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1309 1310 1309 1310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1325 1326 1325 1326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1332 1333 1332 1333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1357 1358 1357 1358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1364 1365 1364 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1385 1386 1385 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1392 1393 1392 1393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1478 1479 1478 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 231 236 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 738 743 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tim-3-expressing cells exhibit impaired Stat-5, p35, and Erk1/2 signaling in response to stimuli. Phosphorylation status of Stat5, p38, and Erk1/2 were analyzed by flow cytometry in Tim-3hi versus Tim-3-/lo CD8+ T cells from three HIV-1-infected subjects. Whole PBMCs were surface stained on ice, stimulated with either rIL-2 for 45 min or P+I for 15 min, and phosphorylation of Stat5 or Erk1/2 and p38, respectively, was analyzed with phosphospecific antibodies in CD3+CD8+ T cells and based on their Tim-3 expression. (a) Shown is a representative flow cytometry gating of Tim-3hi and Tim-3-/lo CD8+ PBMCs evaluating the fold change in p38 phosphorylation after 15 min of stimulation with P+I and summary of data from three chronically HIV-1-infected individuals, each analyzed in triplicates, with fold changes in phosphorylation of stimulated/unstimulated cells. (b) Shown is a representative time course depicting fold change in phosphorylation (stimulated/unstimulated cells) after 15, 30, and 45 min of stimulation. (c-e) Compiled data for Stat5 (c), Erk-1/2 (d), and p38 (e), showing differential levels of change in target phosphorylation (measured by change in mean fluorescence intensity) in Tim-3+ versus Tim-3- cells within each of the following CD3+CD8+ T cell subpopulations: naive (CD27+CD45RA+), memory (CD27+CD45RA-), effector memory (CD27-CD45RA-), or effector (CD27-CD45RA+). Statistical analyses were performed using a nonparametric two-tailed Mann Whitney U test. (*, P </= 0.05; **, P < 0.01; ***, P < 0.001) using Prism GraphPad. Error bars represent SE.
###end p 34
###begin title 35
DISCUSSION
###end title 35
###begin p 36
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 453 454 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 974 975 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 1361 1362 1361 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1447 1448 1447 1448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1589 1590 1589 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2004 2006 2004 2006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 142 147 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 415 420 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 602 607 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 679 684 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 950 953 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 995 1000 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1094 1099 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1343 1348 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1429 1434 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1468 1473 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1571 1576 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Together, these data support that Tim-3 acts to suppress effector functions of activated T cells in chronic uncontrolled viral infection with HIV-1. This complements and integrates previous studies that have identified an important role for Tim-3 in immunoregulation and have implicated defective Tim-3 signaling in the pathogenesis of multiple sclerosis and other autoimmune diseases (31, 44, 45). We show that in HIV-1 infection, the proportion of CD8+ and CD4+ T cells in peripheral blood that express Tim-3 can reach in excess of 70 and 30%, respectively (in contrast to means of 28.5 and 17.6% in HIV-1-uninfected individuals). As these frequencies exceed the proportion of HIV-1-specific cells in the periphery, suppression of T cell function by Tim-3 likely contributes not only to the loss-of-functional virus-specific responses but also to the impairment of responses to other antigens. This is supported by our observation that a subset of CMV and EBV-specific CD8+ T cells in chronic HIV-1-infected individuals expresses high levels of Tim-3 and is consistent with observations that HIV-1-infected individuals have reduced responses to recall antigens and vaccinations (46). The factors leading to this generalized expression of Tim-3 are unknown. Our data does, however, show a disproportionately high level of Tim-3 expression on HIV-1-specific CD8+ T cells, which is consistent with the preferential dysfunction of HIV-1-specific CD8+ T cells in chronic HIV-1 infection. We speculate that the heterogeneity that we observed in levels of Tim-3 expression on HIV-1-specific CD8+ T cell responses may reflect the relative functionality of that response, with greater frequencies of Tim-3-expressing antigen-specific cells associated with more advanced exhaustion and dysfunction. It will also be important to determine whether the fixation of escape mutations results in diminished Tim-3 expression on epitope-specific T cells and improvement in functionality, as has been described for PD-1 (47). These questions will be addressed by future studies.
###end p 36
###begin p 37
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 216 221 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 345 350 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We observed that the initiation of HAART in chronic progressive HIV-1 infection frequently resulted in a decline in Tim-3 expression (four out of seven individuals). However, we observed that a subset of chronically HIV-1-infected individuals on HAART therapy (three out of seven) retained high levels of Tim-3 expression despite suppression of HIV-1 viral load to undetectable levels. Maintenance of Tim-3 expression in the context of HAART was associated with sustained high levels of T cell activation (CD38 expression). Persistence of CD38 expression on T cells during HAART is predictive of disease (32, 48-50). In cases where HAART has failed to result in a reduction in CD38 expression, it has been demonstrated that intensification of HAART by eradicating persistent low-level replication can have a positive impact on immunological parameters, including diminishment of CD38 expression (51).
###end p 37
###begin p 38
###xml 65 70 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 217 222 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 883 888 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our demonstration that blockade of the Tim-3 pathway can enhance HIV-1-specific T cell responses ex vivo clearly demonstrates that the Tim-3 pathway plays a critical role in suppressing the overall T cell response to HIV-1. It should be noted, however, that although T cell exhaustion is associated with increased viral replication, it is unclear whether this phenotype leads to loss of viral control in vivo or whether this loss results primarily from other factors, such as viral escape from CTL epitopes or the persistence of viral replication in sanctuaries inaccessible to CTL. The identification of Tim-3 as a novel mechanism of T cell exhaustion constitutes an important prerequisite for designing studies aimed at delineating the relative contributions of T cell exhaustion versus other factors in the overall inability of the cellular immune response to maintain control of HIV-1 replication.
###end p 38
###begin p 39
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 1241 1242 1241 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1250 1251 1250 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 141 146 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 274 279 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1176 1181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1263 1268 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An important implication of the present study is the possibility that pharmacological agents that block Tim-3 signaling may be of benefit in HIV-1 infection and potentially in other chronic viral diseases. However, it is unclear whether the high level of Tim-3 expressed in HIV-1 infection is the result of a pathological mechanism on the part of the virus to incapacitate the host immune system or if it is a physiological response to chronic immune activation necessary to hold immunopathology in check. With regard to the latter, recent data supporting that a dysregulation of the Tim-3 pathway may contribute to the pathology of multiple sclerosis highlights the importance of Tim-3 in regulating potentially harmful immune responses (30, 31). This situation is analogous to the considerations required in pursuing PD-1 as a therapeutic target. An important distinction of Tim-3 as a therapeutic target is its unique association with T cells that are impaired not only in their survival and proliferative potential but also in their ability to produce cytokine. Thus, blockade of the Tim-3 pathway carries the novel potential to enhance not only the numbers of T cells in HIV-1 infection but also to improve the functionality of both CD8+ and CD4+ T cells in HIV-1-infected individuals. Because a subset of subjects maintain high levels of Tim-3 expression despite seemingly effective HAART regimens, Tim-3 therapeutics may also play a role in reversing immune defects that persist with HAART.
###end p 39
###begin p 40
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 319 324 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 438 443 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The data presented in the present study clearly demonstrate that Tim-3 expression defines a distinct population of exhausted T cells from that of the recently identified PD-1-expressing population. This corroborates a recent study that reported that PD-1-expressing cells comprise only a subpopulation of dysfunctional HIV-1-specific CD8+ T cells in chronic progressors (52). The mechanisms leading to T cell exhaustion in the context of HIV-1 infection are clearly complex and cannot be attributed to a single pathway. It will be intriguing in future studies to explore the possibility of an additive or a synergistic effect of simultaneously blocking both the Tim-3 and PD-1 pathways. Such strategies may allow for a more comprehensive reversal of T cell exhaustion, potentially leading to potent combination therapies.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42
Subjects.
###end title 42
###begin p 43
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 770 771 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 829 830 829 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1101 1102 1101 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1160 1161 1160 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1220 1221 1220 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1353 1354 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1401 1402 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1546 1547 1546 1547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1576 1577 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1632 1633 1632 1633 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1679 1680 1679 1680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2844 2845 2844 2845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2907 2908 2907 2908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 2979 2981 2979 2981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 28 40 <span type="species:ncbi:9606">participants</span>
###xml 191 196 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 216 221 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 256 261 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 353 358 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 443 448 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 575 580 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1325 1332 <span type="species:ncbi:9606">patient</span>
###xml 1806 1811 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1823 1831 <span type="species:ncbi:9606">patients</span>
###xml 2042 2047 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2152 2157 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2173 2178 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2233 2238 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2280 2285 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2386 2391 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2690 2702 <span type="species:ncbi:9606">participants</span>
###xml 2763 2768 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2920 2925 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3021 3026 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3038 3046 <span type="species:ncbi:9606">patients</span>
###xml 3311 3316 <span type="species:ncbi:9606">Human</span>
Subjects were selected from participants in the CIRC Cohort, Toronto, Canada, and the OPTIONS Cohort, University of California San Francisco (UCSF). The CIRC cohort represented acutely/early HIV-1-infected subjects, HIV-1-infected chronic progressors, and HIV-1-infected viral controllers. Acute/early subjects were defined as individuals infected with HIV-1 within the last 4 mo. Chronic progressors were defined as individuals infected with HIV-1 for >1 yr with a CD4+ T cell count decline of >50 cells/mm3/year. Viral controllers were defined as individuals infected with HIV-1 for >1 yr, no evidence of CD4+ T cell count decline, and a viral load of <5,000 copies/ml bDNA. Clinical data for the cohort used in this study were the following: acute/early, absolute CD4+ T cell counts median = 542 and range = 180-1,240 cells/mm3, and viral loads median = 227,567 and range = 79,000 to >500,000 copies/ml; chronic progressors, absolute CD4+ T cell counts median = 250 and range = 132-660 cells/ml, and viral loads median = 50,000 and range = 290-500,000 copies/ml; and viral controllers, absolute CD4+ T cell counts median = 936 and range = 600-1,440 cells/mm3, and viral loads median = 100 and range = 50-250 copies/mm3. The subject with a viral load of 290 copies/ml, defined as a chronic progressor, was included in this patient group based on a CD4+ T cell count that had declined to 200 cells/mm3. The next lowest viral load in the chronic progressor group was 11,608 copies/ml. The chronic progressor with a relatively healthy absolute CD4+ T cell count of 660 cells/mm3 had a viral load of 51,250 copies/ml and exhibited CD4+ T cell count decline. The relatively high CD4+ T cell count in this individual was likely because of their relatively recent infection (13 mo). Controls were obtained from HIV-1-uninfected patients in the same demographic area with a similar age and sex profile and were processed in an identical manner. For the OPTIONS Cohort, baseline samples from all recruited subjects were evaluated to establish their HIV-1 infection status. Screened subjects must meet one of three criteria to be defined as having acute/early HIV-1 infection: (1) HIV-1 RNA >5,000 copies/ml with a negative or indeterminate HIV-1 antibody test; (2) a documented negative HIV-1 antibody test within 6 mo with current seroconversion; or (3) a history compatible with acute/early HIV-1 infection with laboratory confirmation based on a nonreactive less sensitive antibody test. All subjects discuss the advantages and disadvantages of early antiretroviral therapy with study staff and arrangements are made for therapy for those who elect to initiate treatment. Slightly over half of participants decline therapy. A total of 60 individuals with acute/early HIV-1 infection from the OPTIONS cohort were examined in this study. A median CD4+ T cell count of 544 (interquartile range 429.5, 721) cells/mm3 and median HIV-1 viral load of 4.7 (interquartile range 3.66, 5.2) log10 copies/ml. Controls were obtained from HIV-1-uninfected patients from both the Stanford Blood Bank and uninfected individuals from the cohort demographics. Additional subjects on HAART were recruited from these cohorts. This study was approved by the University of Toronto Institutional Review Board and by the UCSF Committee on Human Research, and subjects gave written informed consent. Studies were performed on cryopreserved PBMCs immediately after thawing. At the initiation of this study, a comparison between fresh and frozen PBMCs was performed, and it was found that Tim-3 levels remained proportional after freezing/thawing.
###end p 43
###begin title 44
Peptides and stimulation reagents.
###end title 44
###begin p 45
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Overlapping HIV-1 Clade B Gag and Nef pooled peptides were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. CEF pooled peptides (AnaSpec), SEB (Sigma-Aldrich), and purified anti-CD3 and anti-CD28 monoclonal antibodies (BD) were used as additional reagents. Stimulations were performed with final concentrations of 10 mug/ml peptide.
###end p 45
###begin title 46
Multicolor cytokine flow cytometry.
###end title 46
###begin p 47
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 449 454 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
PBMCs from healthy HIV-1-uninfected and HIV-1-infected individuals were stained with fluorophore-conjugated monoclonal antibodies to CD4, CD8, CD57, CCR7, CD27, CD45RA, CD25, Ki67 (BD), CD28, PD-1 (BioLegend), CD3 (Beckman Coulter), and TIM-3 (R&D Systems) to determine phenotype assessment. An Aqua amine dye (Invitrogen) was used as a discriminating marker for live and dead cells. In some experiments, cells were stimulated after thawing with an HIV-1-Gag and -Nef peptide pool, a CEF peptide pool, or SEB followed by a fixation and permeabilization step. Intracellular staining for cytokines was performed using anti-TNF-alpha and IFN-gamma (BD). Cells were fixed in PBS + 2% paraformaldehyde. Cells were acquired with a modified FACSAria, modified LSRII system, or FACSCalibur (BD). A total of >100,000 events were collected and analyzed with FlowJo software (Tree Star, Inc.). SPICE software (version 3.0; M. Roederer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health) was used to assist in the organization and presentation of multicolor flow data.
###end p 47
###begin title 48
Pentamer/tetramer analyses.
###end title 48
###begin p 49
###xml 153 159 153 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 222 228 222 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 274 279 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
All pentamers were obtained from ProImmune Ltd and all tetramers were obtained from Beckman Coulter. Pentamers were used for the experiment displayed in Fig. 2, whereas tetramers were used for the experiment summarized in Fig. 7. Cryopreserved PBMC samples from chronically HIV-1-infected individuals were thawed and washed with 2 x 10 ml of 1% FBS PBS with 2 mM EDTA. Staining was performed immediately after thawing with fluorophore-conjugated antibodies against CD8 (BD), Tim-3 (R&D Systems), CD3 (BD), and the indicated pentamers (unlabeled), followed by a secondary staining step with APC-labeled pentamer fluorotags. Cells were washed two times with 1% FBS PBS and then fixed in 2% paraformaldehyde. Analysis was performed using a FACSCalibur instrument (BD).
###end p 49
###begin title 50
Synthesis of recombinant Tim-3.
###end title 50
###begin p 51
###xml 291 315 291 315 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CCTCAGAAGTGGAATACAGAGCGG</underline>
###xml 368 389 368 389 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TCTGATGGTTGCTCCAGAGTC</underline>
###xml 1995 1996 1993 1994 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 26 29 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 713 716 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 989 1000 <span type="species:ncbi:3704">horseradish</span>
###xml 1115 1118 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1228 1231 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1487 1490 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1531 1534 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1704 1707 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1753 1756 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1787 1790 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 1855 1858 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 2445 2448 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
###xml 2848 2851 <span type="species:ncbi:12227?0.9375|species:ncbi:11084?0.0390625">TEV</span>
The expression vector pPA-TEV was previously derived from pIRESpuro3 (Clontech Laboratories, Inc.) and modified to incorporate the transin leader sequence and N-terminal protein A tag. The Tim-3 insert was obtained from PCR using the following primers : Tim-3 external forward, 5'-TTCGGCCGGCCCTCAGAAGTGGAATACAGAGCGG-3'; and Tim-3 external reverse, 5'-TGAGCGGCCGCTCATCATCTGATGGTTGCTCCAGAGTC-3'. For each primer, the underlined bases represent the template annealing sequence. Additional 5' sequences comprise restriction sites and stop codons. The region amplified by these primers constitutes only the IgV and mucin domains of Tim-3. The resultant Tim-3 amplicon was cloned into the FseI-NotI cloning site of pPA-TEV. 10 mug of circular DNA plasmid was then transfected into HEK293T cells using the calcium phosphate method (Invitrogen). Expression of Tim-3 was confirmed by Western blot using a 1/5,000 dilution of a polyclonal anti-Tim-3 antibody (R&D Systems) and a 1/5,000 dilution of horseradish peroxidase-conjugated streptavidin (Thermo Fisher Scientific). Transfection was then repeated with linearized pPA-TEV-Tim-3 plasmid to generate stable cell lines. A parallel transfection was performed with empty linearized pPA-TEV. 3 d after transfection, puromycin drug selection was initiated by replacing the media with fresh media supplemented with 1-5 mug/ml puromycin. The media was exchanged with fresh puromycin-containing media every 2 d. 10 d later, six colonies from the pPA-TEV-Tim-3 transfection and six from the pPA-TEV transfection were isolated and expanded into 6-well tissue culture plates. Secreted proteins were detected by Western blot analysis using an anti-Tim-3 antibody for pPA-TEV-Tim-3 and an anti-protein-A antibody for pPA-TEV. A Tim-3-secreting clone (pPA-TEV-Tim-3 transfected) and a control protein A-secreting clone (pPA-TEV transfected) were selected and grown up in 2 liters each of CHO-SFM-II media supplemented with 2% FBS, penicillin, streptomycin, Hepes, l-glutamine, and 1 mug/liter apoprotinin (Sigma-Aldrich) in six T175 tissue culture flasks. Cells were plated at 50% confluency, and protein secretion was allowed to continue for 5 d. Supernatants were concentrated from 2 liters to 10 ml using Centricon Plus-70 centrifugal filter units (Millipore). Proteins were purified using IgG Sepharose 6 Fast Flow beads (GE Healthcare) as per the manufacturer's instructions. 200 mul of 0.33 mg/ml His-tagged TEV protease was then added to the beads, and cleavage was allowed to proceed overnight at 4degreesC. Supernatants were removed from beads, the beads were washed three times with 1 ml Tris-saline Tween, pH 7.2, and supernatants were pooled with wash eluates. This combined eluate was passed through a 1-ml nickel column (B-PER 6x His fusion protein purification kit; Thermo Fisher Scientific) to remove TEV protease and washed with 3 x 2 ml of wash buffer 2 from the same kit. The eluates were subsequently passed through Detoxi-Gel endotoxin removal columns (Thermo FIsher Scientific), according to the manufacturer's instructions, and then concentrated to 0.5 ml using Centricon plus-20 centrifugal filter units (Millipore). Volumes were then adjusted to 15 ml using sterile PBS and reconcentrated to 0.5 ml. The purity and identity of products were confirmed by SDS-PAGE and Western blot analysis. Protein concentration was determined by a Bradford assay. As expected, only small amounts of residual protein were detectable in the protein A control purification. This sample serves as a control for any effect of contaminant proteins or reagents from the purification process on proliferation or cytokine production.
###end p 51
###begin title 52
Proliferation assay.
###end title 52
###begin p 53
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 559 564 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 805 810 <span type="species:ncbi:9606">Women</span>
###xml 988 993 <span type="species:ncbi:9606">human</span>
To track cell division, PBMCs from chronically HIV-1-infected individuals were labeled with 1 mM of the fluorescent intracellular dye CFSE (5-[and -6] carboxyfluorescein diacetate succinimidyl ester; Invitrogen) in PBS and mixed periodically for 10 min at room temperature. Labeling was quenched by addition of an equal volume of complete media (15% FBS in RPMI) for 2 min. The labeled cells were then washed twice, counted, and resuspended in cell culture media. CFSE-labeled cells were stimulated for 5-6 d with either DMSO alone, SLYNTVATL peptide, pooled HIV-1-derived Gag and Nef peptides, or CEF pooled peptides in the presence or absence of sTim-3, an equal volume of expression control, a monoclonal Tim-3-blocking antibody 2E2 (provided by V. Kuchroo, Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115), or an IgG1 isotype control. At the end of the culture period, cells were washed and incubated with a combination of the following conjugated anti-human monoclonal antibodies: CD4, CD8 (BD), and Tim-3 (R&D Systems). Intracellular staining for IFN-gamma, IL-2 (BD), and CD3 (Beckman Coulter) was performed after cells were fixed and permeabilized. Cells were then washed in PBC with 2 mM EDTA and 1% BSA and fixed in 1% paraformaldehyde before being run on an LSRII flow cytometer (BD). Data were analyzed by using FlowJo Software (version 6.4; Tree Star, Inc.).
###end p 53
###begin title 54
Signaling analyses.
###end title 54
###begin p 55
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 306 307 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 368 369 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1332 1333 1319 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Before analyses of cellular signaling, archived PBMCs that had been viably frozen were thawed in 15 ml RPMI cell culture medium (Mediatech, Inc.) containing 5% FBS (RPMI+; Thermo Fisher Scientific), washed in PBS containing 2% FBS (PBS+), and then rested at 5 x 106 cells/ml in RPMI+ at 37degreesC in 5% CO2 overnight. The next day, cells were washed with ice-cold PBS+, transferred to a 96-well V-bottom plate, and stained for cell surface markers with fluorophore-conjugated monoclonal antibodies against CD3, CD8, CD27, CD45RA, and Tim-3 on ice for 40 min. An amine-reactive dye (Invitrogen) was used to stain dead cells. After washing, cells were transferred to PBS containing IL-2 (final concentration, 100 ng/ml; Sigma-Aldrich) or P+I (final concentration, 100 ng/ml and 1 mug/ml, respectively; Sigma-Aldrich) at 37degreesC to induce signaling. Signaling was arrested after 15, 30, and 45 min by immediate fixation, adding 4% paraformaldehyde (final concentration, 2%). After 20-min fixation and subsequent washing, cells were permeabilized in 70% ice-cold methanol for 20 min on ice. Cells were washed and stained with an antibody cocktail containing the phosphospecific antibodies p-Erk1/2(pT202/pY204), p-p38(pT180/pY182), and p-Stat5(pY694) (BD) for 60 min on ice. Before analysis, cells were washed and resuspended in PBS+ with 0.05% formaldehyde. The unstimulated control cells underwent the same manipulations. Cells were analyzed on a customized LSR II Flow Cytometer (BD). Analysis of data was performed using FlowJo. Fold changes in phosphorylation were calculated as the ratio of MFI of stimulated cells over unstimulated cells.
###end p 55
###begin title 56
Quantitative PCR.
###end title 56
###begin p 57
###xml 907 909 895 897 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 1305 1306 1292 1293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Primer sequences were used as follows: TBP forward, GGGCATTATTTGTGCACTGAGA, and TBP reverse, TAGCAGCACGGTATGAGCAACT; GATA-3 forward, TGCATGACTCACTGGAGGAC, and GATA-3 reverse, TCAGGGAGGACATGTGTCTG; T-bet forward, GAGGCTGAGTTTCGAGCAGT, and T-bet reverse, CTGGCCTCGGTAGTAGGACA; and IFN-gamma forward, TCCAAGTGATGGCTGAACTG, and IFN-gamma reverse, CTTCGACCTCGAAACAGCAT. Manufacturer's protocols were followed where applicable, unless otherwise noted. RNA was isolated from samples with Trizol (Invitrogen), resuspended in 44 mul diethylpyrocarbonate water, and treated with DNase using DNA-Free (Applied Biosystems). RNA concentrations were determined by spectrophotometry and matched to the sample with the lowest concentration by dilution with diethylpyrocarbonate-treated water. 4 mul RNA were used for each Superscript III First-Strand Synthesis SuperMix (Invitrogen) RT reaction with 1 mul of 50 muM oligodT20. Parallel reactions lacking the RT enzyme were performed and consistently displayed no amplification in subsequent steps. Real-time PCRs were performed using the Prism 7900HT (Applied Biosystems) in 384-microwell plates. All samples, including the external standards, nontemplate control, and RT controls, were run in triplicate. Each 10-mul reaction contained PCR buffer (Invitrogen), 3 mM MgCl2, 0.2 mM dNTP (Applied Biosystems), 1 nM each of forward and reverse primers (Invitrogen), a 1/50 dilution of ROX reference dye (Sigma-Aldrich), a 3/100,000 dilution of SYBR Green I (Sigma-Aldrich), 0.05 U of Platinum Taq polymerase (Invitrogen), and template DNA. Template was a sevenfold serial dilution of genomic DNA for generation of standard curves, 5 mul of complementary DNA synthesis reactions, or 5 mul of matching RT control. Reaction conditions were 95degreesC for 3 min, followed by 36 cycles of 95degreesC for 15 s, 64degreesC for 15 s, and 72degreesC for 20 s. A final dissociation stage was run to generate a melting curve for verification of amplification product specificity. Real-time PCR was monitored and analyzed by the Sequence Detection System (version 2.0; Applied Biosystems).
###end p 57
###begin title 58
Statistical analyses.
###end title 58
###begin p 59
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
We used mixed effects longitudinal analyses to determine if CD8+ T cell activation levels independently associated with Tim-3 on CD8+ T cells during antiretroviral therapy. We specified a random effect for time and the individual. The models were run in the SAS System 9.2 under Proc Mixed. Other statistical tests used are identified in corresponding figure legends.
###end p 59
###begin title 60
Online supplemental material.
###end title 60
###begin p 61
###xml 557 565 557 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 a</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 161 166 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 677 682 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 812 817 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Fig. S1 shows coexpression profiles of Tim-3 and CD38 in an HIV-1-uninfected individual, an HIV-1-infected chronic progressor with a moderate viral load, and an HIV-1-infected chronic progressor with advanced disease and a high viral load. Fig. S2 shows comparisons of alternative flow cytometry methodologies, including mAb versus polyclonal antibody Tim-3 staining, percentage of CD38 versus CD38 MFI, and percentage of Tim-3 versus Tim-3 MFI. Fig. S3 shows individual subject profiles for the effect of HAART on Tim-3 expression levels (as summarized in Fig. 3 a). Fig. S4 shows the relationship between Tim-3 expression and cytokine (TNF-alpha and IFN-gamma) production in HIV-1-infected and uninfected subjects. Fig. S5 shows the relationship between Tim-3 expression and degranulation (CD107a staining) in HIV-1-infected and -uninfected subjects. Fig. S6 shows Tim-3 expression by CFSE diminution after 5 d of in vitro stimulation. Fig. S7 shows the effect of soluble on IFN-gamma production after 6 d of in vitro stimulation with anti-CD28. Online supplemental material is available at .
###end p 61
###begin p 62
We thank Vijay Kuchroo for generously providing us with the monoclonal anti-Tim-3 antibody 2E2. We would like to thank Kelly S. Macdonald for the use of general laboratory equipment. GAG and NEF consensus peptides and CEF pooled peptides were obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health). We would like to thank Mario Roederer (Vaccine Research Center, National Institutes of Health) for use of the Spice software for data presentation. R.B. Jones, L.C. Ndhlovu, D.F. Nixon, M.A. Ostrowski, and J.M. Rini are named as inventors on a patent application based on this work, which was filed by their respective institutions.
###end p 62
###begin p 63
###xml 507 510 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1286 1289 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
This research was supported by funds from the Canadian Institutes for Health Research (CIHR), UCSF Gladstone Institute of Virology & Immunology Center for AIDS Research (P30 AI027763), the UCSF AIDS Biology Program of the AIDS Research Institute (ARI), and the National Institutes of Health (AI60379, AI68498, AI64520, and AI066917). L.C. Ndhlovu was supported by the Irvington Institute/Dana Foundation Fellowship from the Cancer Research Institute. M.A. Ostrowski received salary support from the Ontario HIV Treatment Network (OHTN) and the CIHR. R.B. Jones receives a studentship from the OHTN. M.P. Sheth was supported by a grant from the University-wide AIDS Research Program (F05-GI-219). J.M. McCune was supported in part by National Institutes of Health grant U01 AI43641, by the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and by the National Institutes of Health Director's Pioneer Award Program, which is part of the National Institutes of Health Roadmap for Medical Research (DPI OD00329). R. Kaul receives salary support from the Canada Research Chair Program and grant support from a CIHR Operating Grant (HOP-81735) and an OHTN Operating Grant. Biosafety level 3 laboratory space and equipment was provided by the Canadian Foundation for HIV Research (CANFAR) in partnership with the Canadian Foundation for Innovation and the Ontario Innovation Trust.
###end p 63
###begin p 64
The authors state that they have no other conflicting financial interests.
###end p 64

